Balanced anticoagulation strategies are essential in managing patients who require both preventive and therapeutic support in thromboembolic conditions. Low molecular weight heparins (LMWH) provide flexibility and predictable clinical outcomes across a wide range of healthcare settings.

NADROBARA® (Nadroparin Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 3800 IU strength supports both prophylactic and therapeutic anticoagulation, enabling healthcare professionals to deliver controlled and effective treatment across regional and international healthcare markets.